Nursing Strategies In the Management of Myelofibrosis A Case-Based Assessment
Hematology-Oncology
Curriculum:
Nursing Strategies In the Management of Myelofibrosis: A Case-Based Assessment
Nursing Strategies In the Management of Myelofibrosis: A Case-Based Assessment
Credits:
0.7 ANCC Contact Hours
0.7 ANCC Contact Hours
Launch Date:
March 11, 2014
March 11, 2014
Expiration Date:
The accreditation for this activity has expired.
The accreditation for this activity has expired.
Primary Audience:
Advanced Practice Nurses, Advanced Practice Registered Nurses, and other nursing professionals
Relevant Terms:
Myelofibrosis
Sandra E. Kurtin, MSN, RN, ANP-C, AOCN®
Sandra E. Kurtin, MSN, RN, ANP-C, AOCN®
The University of Arizona Cancer Center Tucson, AZ
Bio
The University of Arizona Cancer Center
Sandra E. Kurtin is a Nurse Practitioner, Clinical Assistant Professor of Medicine and Adjunct Clinical Assistant Professor of Nursing at The University of Arizona Cancer Center in Tucson, AZ. She has 29 years of oncology nursing experience, 23 of those in advanced practice, 18 as a Nurse Practitioner in oncology. She maintains a busy clinical practice in an NCI-designated Comprehensive Cancer Center with expertise in hematological malignancies, GI malignancies, clinical trials and symptom management.
Ms. Kurtin received her M.S. in nursing from the University of Arizona. She is widely published in peer reviewed journals, lectures nationally and internationally and maintains active membership in local, regional, national and international professional and patient advocacy oncology organizations.
Ms. Kurtin received her M.S. in nursing from the University of Arizona. She is widely published in peer reviewed journals, lectures nationally and internationally and maintains active membership in local, regional, national and international professional and patient advocacy oncology organizations.
Sara M. Tinsley, ARNP, AOCN®
Sara M. Tinsley, ARNP, AOCN®
Moffitt Cancer Center Tampa, FL
Bio
Moffitt Cancer Center
Sara M. Tinsley is currently a Nurse Practitioner for Malignant Hematology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, FL. Sara began her career as a registered nurse at Moffitt in 1990, and became an advanced registered nurse practitioner (ARNP) in 1993. Sara has extensive experience working with individuals diagnosed with hematologic malignancies, initially in the blood and marrow transplant setting, and more recently in malignant hematology.
Ms. Tinsley holds an M.S. in nursing from the University of South Florida, College of Nursing. She is currently a Ph.D. candidate at the University of South Florida, College of Nursing. Her research interest is focused on quality of life in patients with acute myeloid leukemia and high risk myelodysplastic syndrome. She is an accomplished speaker and has written numerous abstracts/publications. Ms. Tinsley has also been a co-investigator in numerous clinical trials, and has been encouraged to see many drug trials result in FDA approved medications for hematologic malignancy patients. Her passion is the provision of excellent patient care.
Ms. Tinsley holds an M.S. in nursing from the University of South Florida, College of Nursing. She is currently a Ph.D. candidate at the University of South Florida, College of Nursing. Her research interest is focused on quality of life in patients with acute myeloid leukemia and high risk myelodysplastic syndrome. She is an accomplished speaker and has written numerous abstracts/publications. Ms. Tinsley has also been a co-investigator in numerous clinical trials, and has been encouraged to see many drug trials result in FDA approved medications for hematologic malignancy patients. Her passion is the provision of excellent patient care.
| 1. | Define and grade myelofibrosis based on current WHO classification and criteria | 2. | Recognize common signs and symptoms associated with myelofibrosis |
| 3. | Discuss the role of chemotherapeutic agents in the treatment of myelofibrosis and assess their clinical benefits | 4. | Evaluate emerging clinical evidence on the safety and efficacy of novel agents for the therapeutic management of myelofibrosis |
| 5. | Implement effective symptom and side effect management strategies to optimize outcomes for patients treated for myelofibrosis |
| 1. | Define and grade myelofibrosis based on current WHO classification and criteria |
| 2. | Recognize common signs and symptoms associated with myelofibrosis |
| 3. | Discuss the role of chemotherapeutic agents in the treatment of myelofibrosis and assess their clinical benefits |
| 4. | Evaluate emerging clinical evidence on the safety and efficacy of novel agents for the therapeutic management of myelofibrosis |
| 5. | Implement effective symptom and side effect management strategies to optimize outcomes for patients treated for myelofibrosis |
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 5.0+ for Mac OSX 10.5 and above For video playback, install the latest version of Flash or Quicktime. |
ACCREDITATION STATEMENT
Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
Provider is approved by the California Board of Registered Nursing, Provider #13485, for 0.7 contact hours.
CREDIT DESIGNATION
This educational activity for 0.7 contact hours is provided by Postgraduate Institute for Medicine.
This activity is also designated for 0.2 contact hours of pharmacotherapy credit for Advance Practice Registered Nurses.
DISCLOSURE OF CONFLICTS OF INTEREST
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Sandra E. Kurtin, MS, RN, ANP-C, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Celgene Corporation, Incyte Corporation, Novartis Pharmaceuticals Corporation.
Sara M. Tinsley, PhDc, MS, ARNP, AOCN®, reported a financial interest/relationship or affiliation in the form of: Advisory Board, Amgen, Inc., Genentech, Inc.; Speakers' Bureau, Ariad Pharmaceuticals, Inc., Bristol-Myers Squibb Company, Genentech, Inc., Incyte Corporation, Novartis Pharmaceuticals Corporation.
The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
The following AXIS planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Linda Gracie-King, MS and Diedrea White, BA, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.
SAFEGUARDS AGAINST COMMERCIAL BIAS
Postgraduate Institute for Medicine and AXIS affirm that the content and format of its CME/CE activities and related materials promote improvements and quality in healthcare and do not promote a specific proprietary business interest of a commercial entity. To this end, Postgraduate Institute for Medicine and AXIS employ several strategies to ensure the absence of commercial bias, including but not limited to review of all planned content for CME/CE activities jointly sponsored by Postgraduate Institute for Medicine and AXIS to ensure adherence to the Accreditation Council for Continuing Medical Education's and American Nurses Credentialing Center's Commission (ANCC) on Accreditation's content validation statements and resolution of any actual or perceived conflict of interest that exist. We employ three metrics as we review materials:
- Fair balance
- Recommendations or emphasis must fairly represent and be based on a reasonable and valid interpretation of the information available on the subject matter
- No single product or service is overrepresented when other equal competing products or services are available for inclusion
- Scientific objectivity of studies mentioned in the materials or used as the basis for content
- Appropriateness of patient care recommendations made to learners
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
METHOD OF PARTICIPATION
To receive acknowledgement of participation for this CME-certified activity, you must complete the evaluation and pass the posttest online with a score of 65% or better in a maximum of 5 attempts. You may print and/or download your certificate upon completion.
ESTIMATED TIME TO COMPLETE ACTIVITY: 45 minutes
FEE STATEMENT
There is no fee for this educational activity.
CONTACT INFORMATION
To contact PIM, please visit www.pimed.com.
Co-provided by:
Supported through independent educational grants from Sanofi US and Incyte Corporation.
